Last reviewed · How we verify
subcutaneous progesterone
At a glance
| Generic name | subcutaneous progesterone |
|---|---|
| Also known as | Pleyris, Protulex, Prolutex |
| Sponsor | Bezmialem Vakif University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. (PHASE4)
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles (NA)
- Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients (PHASE4)
- Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters (PHASE4)
- Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer. (PHASE3)
- Trial Comparing Subcutaneous Natural Progesterone (Prolutex) vs. Cetrorelix Acetate for Luteinizing Hormone Surge Suppression in Freeze-All IVF Cycles. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- subcutaneous progesterone CI brief — competitive landscape report
- subcutaneous progesterone updates RSS · CI watch RSS
- Bezmialem Vakif University portfolio CI